Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 89-99

  Brown Glaberman, Ursa ^a   Stopeck, Alison T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Bone metastases; Breast cancer; Denosumab; Prostate cancer; Skeletal complications; Skeletal related events; Solid tumor

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PLACEBO; ZOLEDRONIC ACID;

ADVERSE OUTCOME; ASTHENIA; BACKACHE; BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CHILL; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FLU LIKE SYNDROME; FRACTURE; HEADACHE; HUMAN; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; MALAISE; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; THORAX PAIN; TREATMENT DURATION; TREATMENT PLANNING;

EID: 84866766259     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80(Suppl 8):1588-1594.
2. Coleman RE. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1):61-66.
3. Mercandante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1-2):1-18.
4. Lipton A. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer. 2000(5);88:1082-1090.
5. Rosen LS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer. 2004;100(12): 2613-2621.
6. Saad F. Clinical benefits of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer. 2005;4(1):31-37.
7. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol. 1991;18 Suppl 5:11-15.
8. Kohno N. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-3321.
9. Rosen LS. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least on osteolytic lesion. Cancer. 2004;100(1):36-43.
10. Sadd F, Gleason DM, Murray R, et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19): 1458-1468.
11. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735-1744.
12. Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2001.
13. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2005;20(12): 2275-2282.
14. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
15. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153-161.
16. Eastell R. Aromatase inhibitors and bone. J Steroid Biochem Mol Biol. 2007;106(1-5):157-161.
17. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21): 4042-4057.
18. NCCN Guidelines Version 1.2012 Breast Cancer. 01/20/12. National Comprehensive Cancer Network Inc. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed February 14, 2012.
19. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875-4882.
20. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745-755.
21. Xgeva® [package insert]. Thousand Oaks, CA: Amgen Inc; 2010.
22. Fizazi K, Lipton A, Mariette X, et al. Randomized Phase II trial of denosumab in patients with one metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564-1571.
23. Lipton A, Steger CG, Figueroa J. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancerrelated bone metastases. J Clin Oncol. 2001;25(28):4431-4437.
24. Tabrizi MA, Tseng CM, Roskos LE, et al. Elimination mechanism of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1-2): 81-88.
25. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-323.
26. Miller PD, Wagman RB, Peacock M, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six year results of a phase 2 clinical trial. J Clin Endocrinol Metab. 2011; 96(2):394-402.
27. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blinded study. J Clin Oncol. 2010;28(35):5132-5239.
28. Stopeck A, Martin M, Ritchie D, et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Abstract P6-14-01, presented at San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX.
29. Stopeck A, Lipton A, Campbell-Baird C, et al. Acute-phase reaction following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 Study in patients with breast cancer and bone metastases. Abstract P6-14-09, presented at San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX.
30. Fallowfield L, Patrick D, Body J, et al. Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: Results from a randomized phase III trial. Abstract number 1025, presented at the ASCO annual meeting, June 4-8, 2010, Chicago, IL.
31. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29(16):1221-1227.
32. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for the treatment of bone metastases in men with castrationresistant prostate cancer: a randomized, double-blind study. Lancet. 2011;377(9768):813-822.
33. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97 (1):59-69.
34. NCCN Guidelines Version 1.2012 Prostate Cancer. 02/22/12. National Comprehensive Cancer Network Inc. Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed February 14, 2012.
35. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2001;29(9):1125-1132.
36. Richardson GE, Ciuleanu TE, Costa L, et al. Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis. Abstract number 9115, presented at the ASCO annual meeting, June 3-7, 2011, Chicago, IL.
37. von Moos R, Patrick D, Fallowfield L, et al. Effects of denosumab versus zoledronic acid on pain in patients with advanced cancer (excluding breast and prostate) or multiple myeloma: Results from a randomized phase III clinical trial. Abstract number 9043, presented at the ASCO annual meeting, June 4-8, 2010, Chicago, IL.
38. Lipton A, Fizazi K, Stopeck A, et al. Prevention of skeletal-related events with denosumab or zoledronic acid: combined analysis from 3 registrational trials. Abstract number 3061, presented at the European Multidisciplinary Cancer Congress, September 23-27, 2011, Stockholm, Sweden.
39. Diel IJ, Body JJ, Stopeck A, et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with bone metastasis. Abstract number 3051, presented at the European Multidisciplinary Cancer Congress, September 23-27, 2011, Stockholm, Sweden.
40. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2011. Epub Oct 10.
41. Stopeck AT, Lipton A, Martin M, et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2-year open-label extension treatment phase of a pivotal phase 3 study. Abstract P3-16-07, presented at the San Antonio Breast Cancer Symposium, December 6-10, 2011, San Antonio, TX.
42. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1): 72-81.
43. Gnant M, Mineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(22):679-691.
44. Coleman RE, Marshall H, Cameron D. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1397-1405.
45. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440(7084): 692-696.
46. Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). Available from: http://clinicaltrials.gov/ct2/show/NCT01077154. Accessed December 15, 2011.
47. Rodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-1664.
48. Smith M, Saad F, Coleman R, et al. Denosumab and bone-metastasisfree survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial. Lancet. 2012;379(9810): 39-46.